BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

BridgeBio Pharma, Inc.

BridgeBio finds, develops, and delivers breakthrough medicines for genetic diseases.

Millions worldwide are afflicted with genetic diseases, but small patient populations and industry reluctance to conduct early-stage development means that for many, treatments have not been forthcoming. We are committed to bridging this gap: between business case and scientific possibility, between patient and hope. BridgeBio creates a bridge from remarkable advancements in genetic science to patients with unmet needs via the entrepreneurial engine required to make life-changing medicines as rapidly as possible.

BridgeBio is committed to developing leaders as well as drugs. We are looking for individuals whose passion for creating life-changing medicines will inspire hands-on engagement and the dogged pursuit of novel solutions in the face of adversity.

MyoKardia

Eidos Therapeutics

Blue Owl

CPP Investments

Qatar Investment Authority

Perceptive Advisors

Janus Fund

Viking Global Investors

Cormorant Capital

Kohlberg Kravis Roberts

Hercules Capital

AIG Investments

Sequoia Capital

Aisling Capital

BridgeBio

Our chief medical officer at BridgeBio Gene Therapy, 👤 Adam Shaywitz, M.D., Ph.D., will chair a panel today at the PMWC - Precision Medicine World Conference on novel clinical design approaches in rare diseases. Learn more about his session here: https://bit.ly/3vwZsdq

This week Dunni Odumosu, MS, vice president of regulatory affairs at BridgeBio Gene Therapy will lead a workshop at the Gene Therapy Regulatory Affairs Summit on the key learnings and best practices for optimizing regulatory interactions in the rapidly evolving field of gene therapy. Check out the agenda: https://bit.ly/3TWKJTs

In our latest episode of #OnRare we were privileged to speak with Effie Parks, a rare mom, a patient advocate, a podcaster, and host of “Once Upon a Gene.” Effie candidly shares her experience of being a new mom to a child living with a rare condition and her journey into the advocacy space. https://bit.ly/47H0S2q

We appreciate the partnership with the limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9) advocacy groups and applaud their many achievements. We are excited to continue working on behalf of the LGMD community and to see what is next for 2024. Together We Are Stronger!

We are proud to share that the positive results from our Phase 3 ATTRibute-CM study have been published in the NEJM Group. We submitted our New Drug Application for acoramidis to the U.S. FDA in 2023 and intend to submit additional marketing authorization applications to regulatory bodies this year. Learn more: https://bit.ly/3TPN8iF

Thank you JPMorgan Chase & Co. for inviting us to present at the Annual Healthcare Conference! Our CEO and founder, Neil Kumar, Ph.D. shared our learnings across the ATTR-CM space since last year as well as provided updates on our late-stage programs, our research & early development candidates, and our priorities for 2024. #JPM24 Listen to our presentation here: https://bit.ly/3H3uL2b

To wrap up our 2023, our On Rare team recalled the wonderful, rare conversations we held with our extraordinary guests. Join us for a look back at 2023 and don’t forget to subscribe to learn more from our guests in 2024. https://bit.ly/3tL5rLd

BridgeBio founder & CEO Neil Kumar, Ph.D. is presenting at the J.P. Morgan 42nd Annual Healthcare Conference today at 8:15 a.m. PT. Join and learn about our goal to develop medicines for people with genetic diseases and cancers. Listen to the presentation here: https://bit.ly/3H3uL2b

We are on a mission to discover, create, test, and deliver transformative medicines to treat patients with genetic diseases and cancers. Learn more about our upcoming presentation at the J.P. Morgan Annual Healthcare Conference, where we will discuss our milestones for the year. Read more: https://bit.ly/3H6969k

The U.S. FDA has cleared our investigational new drug (IND) application for BBO-8520, a first-in-class orally bioavailable and potentially highly potent small molecule direct inhibitor of KRASG12C. We intend to begin enrollment of patients with KRASG12C mutant non-small cell lung cancer into our ONKORAS-101 trial, which is expected to begin in the first half of this year. Learn more: https://bit.ly/3H5JyJB

	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
net income	-43.83M -	-169.45M 286.59%	-288.58M 70.31%	-505.49M 75.16%	-586.45M 16.02%	-484.65M 17.36%	-653.25M 34.79%
depreciation and amortization	260K -	245K 5.77%	859K 250.61%	3.09M 259.49%	5.84M 89.22%	6.77M 15.88%	6.49M 4.09%
deferred income tax	-260K -	-14.89M 5,626.92%	-859K 94.23%	-1.87M 117.23%	-30.93M 1,557.56%		-18.06M -
stock based compensation	1.84M -	6.07M 229.55%	21.37M 252.30%	58.46M 173.51%	99.50M 70.21%	91.56M 7.99%	108.71M 18.73%
change in working capital	1.24M -	22.49M 1,709.41%	-10.91M 148.53%	14.93M 236.82%	-4.40M 129.44%	28.08M 738.74%	5.06M 81.99%
accounts receivables			-2.85M -	2.85M 200%	-19.75M 794.17%	15.17M 176.81%	15.33M 1.05%
inventory			2.85M -	-2.85M 200%	19.75M 794.17%	-15.17M 176.81%	-15.33M 1.05%
accounts payables	1.58M -	16.70M 958.97%	-4.66M 127.89%	-735K 84.22%	2.83M 485.44%	-349K 112.32%	2.78M 896.56%
other working capital	-334K -	5.79M 1,833.83%	-6.26M 208.06%	15.67M 350.38%	-7.23M 146.14%	28.43M 493.25%	2.28M 91.99%
other non cash items	260K -	18.89M 7,167.31%	24.54M 29.87%	31.16M 26.98%	18.50M 40.63%	-61.25M 431.12%	23.33M 138.08%
net cash provided by operating activities	-40.49M -	-136.64M 237.49%	-253.59M 85.58%	-399.71M 57.62%	-497.93M 24.57%	-419.49M 15.75%	-527.72M 25.80%
investments in property plant and equipment	-464K -	-18.18M 3,817.67%	-5.14M 71.74%	-7.52M 46.32%	-48.25M 541.74%	-6.32M 86.90%	-1.31M 79.34%
acquisitions net		-2.86M -	-5.49M 92.13%	21.24M 486.83%	-35M 264.78%	120M 442.86%
purchases of investments			-212.90M -	-287.85M 35.21%	-643.27M 123.47%	-193.06M 69.99%	-137.26M 28.90%
sales maturities of investments			5.49M -	242.23M 4,311.40%	477.04M 96.94%	532.52M 11.63%	193.11M 63.74%
other investing activites			784K -	-21.09M 2,790.56%	48.65M 330.65%		-503K -
net cash used for investing activites	-464K -	-21.04M 4,433.62%	-217.25M 932.77%	-52.99M 75.61%	-200.83M 278.97%	453.15M 325.64%	54.03M 88.08%
debt repayment		-1.10M -	-175.78M 15,923.79%	-536.96M 205.47%	-124.12M 76.88%	-20.49M 83.49%
common stock issued		95.54M -	366.24M 283.35%	1.21M 99.67%	3.82M 217.10%	4.85M 26.98%	449.81M 9,170.61%
common stock repurchased			175.78M -	-75.71M 143.07%	-204.75M 170.42%	-1.56M 99.24%	-6.88M 340.74%
dividends paid	-1.15M -		-997K -	-536.96M 53,757.67%	-3.82M 99.29%
other financing activites	114.13M -	407.11M 256.69%	33.55M 91.76%	1.60B 4,655.66%	1.07B 33.24%	4.06M 99.62%	8.61M 111.89%
net cash used provided by financing activities	112.98M -	501.55M 343.91%	398.79M 20.49%	447.19M 12.14%	736.45M 64.68%	-13.13M 101.78%	451.54M 3,537.91%
effect of forex changes on cash
net change in cash	72.03M -	343.87M 377.39%	-72.05M 120.95%	-5.52M 92.34%	37.69M 782.96%	20.52M 45.55%	-22.15M 207.96%
cash at beginning of period	20.34M -	92.38M 354.05%	436.25M 372.25%	364.20M 16.52%	358.68M 1.52%	396.37M 10.51%	416.88M 5.18%
cash at end of period	92.38M -	436.25M 372.25%	364.20M 16.52%	358.68M 1.52%	396.37M 10.51%	416.88M 5.18%	394.73M 5.31%
operating cash flow	-40.49M -	-136.64M 237.49%	-253.59M 85.58%	-399.71M 57.62%	-497.93M 24.57%	-419.49M 15.75%	-527.72M 25.80%
capital expenditure	-464K -	-18.18M 3,817.67%	-5.14M 71.74%	-7.52M 46.32%	-48.25M 541.74%	-6.32M 86.90%	-1.31M 79.34%
free cash flow	-40.95M -	-154.82M 278.05%	-258.73M 67.11%	-407.23M 57.40%	-546.18M 34.12%	-425.81M 22.04%	-529.03M 24.24%

COM:BRIDGEBIO

BridgeBio Pharma, Inc.

Last Close

23.04

21/11 21:00

Market Cap

4.97B

Beta: -

Volume Today

2.07M

Avg: -

Preview